Is Immix Biopharma, Inc. (IMMX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 3.6% / 30% | 0.4% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 3.6% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| MSCI | 4.7% / 33% | 77.1% / 33% | 8.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 3.6% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| FTSE | 4.7% / 33% | 77.1% / 33% | 8.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -55.0% | |
| Return on Assets (ROA) | -29.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$16M |
| Total Debt | $1M |
| Debt-to-Equity | 1.1 |
| Current Ratio | 10.0 |
| Total Assets | $23M |
Price & Trading
| Last Close | $8.72 |
| 50-Day MA | $7.72 |
| 200-Day MA | $4.39 |
| Avg Volume | 881K |
| Beta | 0.3 |
|
52-Week Range
$1.34
| |
About Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immix Biopharma, Inc. (IMMX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immix Biopharma, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immix Biopharma, Inc.'s debt ratio?
Immix Biopharma, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.7%.
What are Immix Biopharma, Inc.'s key financial metrics?
Immix Biopharma, Inc. has a market capitalization of $432M. Return on equity stands at -55.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.